Ajinomoto AminoScience introduces new resource for peptides

AjiPhase™ enables the use of a single peptide synthesis methodology throughout therapeutic peptide development, negating the need to transition between solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) methodologies as peptide requirements increase. The use of a single synthetic methodology eliminates the need for additional development time required in switching from solid to liquid phase methods and also removes the need to revalidate the impurity profile when transitioning synthetic methods.

"For scientists in pharmaceutical and biotechnology product development, AjiPhase™ gives the benefits of SPPS with its efficient removal of un-reacted reagents," stated Dr. Dwayne Allen, business manager of biotechnology, Ajinomoto AminoScience. "Those in R&D and business development roles appreciate the cost advantage of larger scale synthesis, as it is not limited by starting material linked to a solid support. This greatly increases the commercial viability of peptides, gives companies access to higher-purity peptides and reduces development time."

By leveraging the best of both solid and liquid phases, AjiPhase™ provides a financially-feasible way to advance complex peptides through the development pipeline in a timely manner. Combining the benefits of SPPS with the convergent synthesis ability of LPPS, AjiPhase™ makes more complex peptides accessible that may have been too impractical or expensive to manufacture.

"Long-recognized as the leader in amino acid R&D and production technology, Ajinomoto continually pushes ahead with new technology and service offerings. With the launch of AjiPhase™, pharmaceutical and biotechnology companies of all sizes now have new resource for their peptide needs as well as a partner with experience in process development, QA/QC, analytical services and regulatory support," stated Jack Heaton, president of Ajinomoto AminoScience, LLC.